SCHEMBL2837574

SCHEMBL2837574

CC(C)(C)OC(=O)NC(C(=O)c1ccc(OCC(F)(F)C(F)(F)F)cc1F)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.50
MAOB P27338 2/20 0.41
MAOA P21397 1/20 0.41
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
HTRA1 Q92743 4/20 0.37
TRPA1 O75762 1/20 0.36
P2RY2 P41231 1/20 0.36
PTPN1 P18031 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
CYP11B1 P15538 3/20 0.35
CYP11B2 P19099 3/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2839346 0.78 MAOB (0.44) S1PR3MAOBMAOAMAPTCYP11B1
SCHEMBL2834202 0.73 S1PR3 (0.41) S1PR3KDM4EALDH1A1MAPT
SCHEMBL2836695 0.73 S1PR3 (0.41) S1PR3CTSSCTSKPTPN1
SCHEMBL2834216 0.71 RAB9A (0.40) S1PR3KDM4EALDH1A1MAPTHPGD
SCHEMBL17391319 0.71 S1PR3 (0.48) S1PR3CTSSCTSKTRPA1P2RY2
SCHEMBL15974097 0.71 S1PR3 (0.48) S1PR3CTSSCTSKTRPA1P2RY2
SCHEMBL15974098 0.71 S1PR3 (0.48) S1PR3CTSSCTSKTRPA1P2RY2
SCHEMBL2834826 0.71 AAK1 (0.45) S1PR3TRPA1ALDH1A1GAAMAPT
SCHEMBL1525552 0.70 S1PR3 (0.52) S1PR3CTSSCTSKTRPA1P2RY2
SCHEMBL1525463 0.70 S1PR3 (0.52) S1PR3CTSSCTSKTRPA1P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MAOB 287/4885MAOA 279/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MAOB 287/4885MAOA 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.